/PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Amneal Pharmaceuticals, Inc. ("Amneal" or the "Company") (NYSE: AMRX). Such...
Stocks that traded heavily or had substantial price changes on Wednesday: MP Materials, Wolfspeed rise; Amneal, Knight-Swift fall
The company received a complete response letter from the FDA regarding a Parkinson's disease generic therapy.
Amneal Pharmaceuticals, Inc. (NYSE: AMRX) (“Amneal” or the “Company”) announced its actual results today for the first quarter ended March 31, 2023.
Theravance Bio (TBPH) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Amneal (AMRX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.